A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Genentech, Inc.80 enrolled

Overview

This open-label, multicenter, randomized study compared the efficacy, safety and pharmacokinetics of obinutuzumab (RO5072759; GA101) 1000 mg versus 2000 mg in participants with previously untreated CLL. Participants were randomized to receive a maximum of 8 cycles (28-day cycle) of obinutuzumab (1000 mg intravenous \[IV\] infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of each subsequent cycle up to 8 cycles or maximum of 8 cycles of obinutuzumab (2000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of each subsequent cycle up to 8 cycles.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lymphocytic Leukemia, Chronic

Interventions

Obinutuzumab

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed diagnosis of CD20-positive B-cell CLL (per International Workshop on Chronic Lymphocytic Leukemia \[IWCLL\] guidelines) * Rai Stage III/IV or Binet Stage C disease, or Rai Stage I/II or Binet Stage B disease that requires treatment according to IWCLL guidelines * No previous treatment for CLL chemotherapy, radiotherapy or immunotherapy; no previous rituximab treatment for autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP); prior use of steroids for AIHA or ITP is allowed * Eastern Cooperative Oncology Group performance status of 0, 1 or 2 Exclusion Criteria: * Confirmed diagnosis of Transformation of CLL to aggressive B-cell malignancy * History of severe allergic or anaphylactic reactions to monoclonal antibody therapy * Evidence of severe, uncontrolled concomitant disease * Known active infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks before the start of Cycle 1 * Seropositive for human immunodeficiency virus (HIV) * Positive for chronic hepatitis B infection (defined as positive hepatitis B surface antigen \[HBsAg\] serology) * Positive for hepatitis C (hepatitis C virus \[HCV\] antibody serology testing) * Pregnant or lactating women * Concurrent (or within 7 days prior to first dose of study treatment) systemic corticosteroid use, except for low-dose corticosteroid therapy used to treat chronic medical conditions

Locations (31)

Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr

Birmingham, Alabama, United States

Arizona Oncology

Tucson, Arizona, United States

Arizona Clinical Research Ctr

Tucson, Arizona, United States

University of California; Moores Cancer Center

La Jolla, California, United States

USC Norris Cancer Center

Los Angeles, California, United States

Outcomes

Primary Outcomes

Objective Response Rate (ORR)

ORR was defined as the percentage of participants with complete response (CR), CR with incomplete marrow recovery (CRi) or partial response (PR) as assessed by the investigator according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines two months after last treatment. CR required: blood lymphocytes \< 4 x 10\^9/Liter (L), absence of lymphadenopathy (≤ 1.5 centimeter (cm) in long axis by Computed Tomography), no hepatomegaly or splenomegaly, absence of disease, Neutrophils \> 1.5 x 10\^9/L, Platelets \> 100 x 10\^9/L, Hemoglobin \>11 g/dL, bone marrow normal and lymphoid nodules absent. CRi was CR with incomplete marrow recovery. PR required: 50% decrease in peripheral blood lymphocyte count, 50% reduction in lymphadenopathy, 50% reduction of liver and/or spleen enlargement if enlarged at baseline, Neutrophils \> 1.5 x 10\^9/L or \> 50% of pretreatment value, Platelets \> 100 x 10\^9/L or 50% of pretreatment value and Hemoglobin \> 11 g/dL or \> 50% of pretreatment value.

Time frame: Week 32

Secondary Outcomes

Progression-free Survival (PFS)

PFS was defined as the time from the randomization to the first occurrence of progression or death, whichever occurred first.

Time frame: Up to 4 years, 5 months

Duration of Response

Time frame: Up to 4 years, 5 months

Number of Participants Surviving at End-of-Study

Time frame: Up to 4 years, 5 months

Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. A SAE was any AE that was one of the following: fatal, life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product or considered a significant medical event by the investigator. Additional information about AEs can be found in the Adverse Event Section.

Time frame: Up to 4 years, 5 months

Percentage of Participants With Adverse Events of Interest

Adverse Events of interest for this study were: serious infusion related reactions during or within 24 hours of infusion, serious neutropenia, serious infection, tumor lysis syndrome and Hepatitis B reactivation.

Time frame: Up to 4 years, 5 months

Percentage of Participants With Adverse Events Leading to Study Discontinuation

Time frame: Up to 4 years, 5 months

PK Parameter: Maximum Serum Concentration (Cmax)

Blood was collected for Pharmacokinetic (PK) Parameter Cmax after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in micrograms per milliliter (μg/mL).

Time frame: Day 148 (at end of infusion)

PK Parameter: Area Under the Serum Concentration-Time Curve Between Dosing Interval Tau (AUCt )

Blood was collected for PK Parameters before and after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in day times micrograms per milliliter (day\*μg/mL).

Time frame: Day 148 (pre-infusion, at end of infusion, 5, 8 and 12 days after start of infusion)

PK Parameter: Clearance at Steady State (CLss)

Blood was collected for PK Parameters before and after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). CLss is reported in milliliters per day (mL/day).

Time frame: Day 148 (pre-infusion, at end of infusion, 5, 8 and 12 days after start of infusion)

PK Parameter: Volume of Distribution at Steady State (Vss)

Time frame: Day 148 (pre-infusion, at end of infusion, 5, 8 and 12 days after start of infusion)

PK Parameter: Terminal Half-Life (t1/2)

Time frame: Day 148 (pre-infusion, at end of infusion, 5, 8 and 12 days after start of infusion)

PK: Serum Concentrations of Obinutuzumab (Follow-Up Visits)

Blood serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in micrograms per milliliter (μg/mL).

Time frame: Months 3, 6, 9, and 12

Pharmacodynamics: Number of Participants With Peripheral Blood B-cell Depletion

Blood was sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry. B-cell depletion was defined as a CD19 result \< 0.07 × 10\^9/L after at least one dose of study drug has been administered.

Time frame: Up to 4 years, 5 months

Pharmacodynamics: Number of Participants With Peripheral Blood B-cell Recovery

Blood was sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry. B-cell recovery was defined as a CD19 result ≥ 0.07 × 10\^9/L, where CD19 was previously depleted. B-cell recovery was only considered possible following the last dose of study treatment. The number of participants with B-cell recovery from End of Treatment to 6 months of Follow-up is reported in two categories: Recovery with Progressive Disease (PD) \[PD before B-cell recovery or PD within 45 days after recovery\] or Recovery without PD. PD required one of the following: 50% increase in the absolute number of circulating lymphocytes, Appearance of new palpable lymph nodes, 50% increase in the longest diameter of any previous site of lymphadenopathy, 50% increase in the enlargement of the liver and/or spleen or Transformation to a more aggressive histology.

Time frame: Up to 4 years, 5 months